1373762-71-0

Basic information

• Product Name: 7-((5-((2-(4-chlorophenyl)-2-oxoethyl)thio)-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one
• Synonyms: 7-((5-((2-(4-chlorophenyl)-2-oxoethyl)thio)-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one
• CAS NO: 1373762-71-0
• Molecular Weight: 442.88
• Mol File: 1373762-71-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 7-((5-((2-(4-chlorophenyl)-2-oxoethyl)thio)-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-((5-((2-(4-chlorophenyl)-2-oxoethyl)thio)-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one(1373762-71-0)
• EPA Substance Registry System: 7-((5-((2-(4-chlorophenyl)-2-oxoethyl)thio)-1,3,4-oxadiazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one(1373762-71-0)

Safety Data

• Hazardous Substances Data: 1373762-71-0(Hazardous Substances Data)

Upstream product

• 69560-78-7 2-<((4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy)methyl>-1,3,4-oxadiazole-5-thiol 
• 108-46-3 recorcinol 
• 536-38-9 4-chlorobenzoylmethyl bromide 
• 69321-36-4 2-(4-methyl-2-oxo-2H-chromen-7-yloxy)-acetohydrazide 
• 90-33-5 7-hydroxy-4-methyl-chromen-2-one 
• 5614-82-4 ethyl 2-(4-methyl-2-oxo-2-coumarin-7-yloxy)acetate 

Relevant articles and documents

Synthesis and biological evaluation of coumarin-1,3,4-oxadiazole hybrids as selective carbonic anhydrase IX and XII inhibitors

With an aim to develop novel heterocyclic hybrids as potent anticancer agents, we synthesized a series of coumarin-1,3,4-oxadiazole hybrids (7a-t) and evaluated for their inhibitory activity against the four physiologically relevant human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms CA I, CA II, CA IX and CA XII. The CA inhibition results clearly indicated that the coumarin-1,3,4-oxadiazole derivatives (7a-t) exhibited selective inhibition of the tumor associated isoforms, CA IX and CA XII over CA I and II isoforms. Among all, compound 7b, exhibited significant inhibition in lower micromolar potency against hCA XII, with a Ki of 0.16 μM and compound 7n, exhibited significant inhibition in lower micromolar potency against hCA IX, with a Ki of 2.34 μM respectively. Therefore, compound 7b and 7n could be the potential leads for development of selective anticancer agents by exhibiting a novel mechanism of action through hCA IX and XII inhibition.